Legend's five-year data suggests Carvykti could be a cure; Addex, Indivior split

Plus news about Amberstone, Henlius and Boehringer Ingelheim. Legend adds to argument for Carvykti as a cure: Legend Biotech said Friday that 10 of 20 relapsed/refractory multiple myeloma patients who received ...